Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy
Open Access
- 20 July 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8), 1105
- https://doi.org/10.3390/pharmaceutics13081105
Abstract
Rho-associated kinase (ROCK) activation was shown to contribute to microvascular closure, retinal hypoxia, and to retinal pigment epithelium (RPE) barrier disruption in a rat model of diabetic retinopathy. Fasudil, a clinically approved ROCK inhibitor, improved retinal perfusion and reduced edema in this model, indicating that ROCK inhibition could be a promising new therapeutic approach for the treatment of diabetic retinopathy. However, due to its short intravitreal half-life, fasudil is not suitable for long-term treatment. In this study, we evaluated a very potent ROCK1/2 inhibitor (BIRKI) in a depot formulation administered as a single intravitreal injection providing a slow release for at least four weeks. Following BIRKI intravitreal injection in old Goto-Kakizaki (GK) type 2 diabetic rats, we observed a significant reduction in ROCK1 activity in the retinal pigment epithelium/choroid complex after 8 days and relocation of ROCK1 to the cytoplasm and nucleus in retinal pigment epithelium cells after 28 days. The chronic ROCK inhibition by the BIRKI depot formulation restored retinal pigment epithelial cell morphology and distribution, favored retinal capillaries dilation, and reduced hypoxia and inner blood barrier leakage observed in the diabetic retina. No functional or morphological negative effects were observed, indicating suitable tolerability of BIRKI after intravitreous injection. In conclusion, our data suggest that sustained ROCK inhibition, provided by BIRKI slow-release formulation, could be a valuable treatment option for diabetic retinopathy, especially with regard to the improvement of retinal vascular infusion and protection of the outer retinal barrier.This publication has 36 references indexed in Scilit:
- Novel approaches for treating diabetic retinopathy based on recent pathogenic evidenceProgress in Retinal and Eye Research, 2015
- Ripasudil: First Global ApprovalDrugs, 2014
- Intravitreal Fasudil Combined With Bevacizumab for Persistent Diabetic Macular EdemaJAMA Ophthalmology, 2013
- Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachmentCell Death & Disease, 2013
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- ROCK as a Therapeutic Target of Diabetic RetinopathyJournal of Ophthalmology, 2010
- Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular DamageDiabetes, 2009
- Rho Kinase-Mediated Reduction in Cardiac Capillary Endothelial Cell Dimensions, In Situ, Against FlowMicrocirculation, 2008
- Pericyte Rho GTPase Mediates Both Pericyte Contractile Phenotype and Capillary Endothelial Growth StateThe American Journal of Pathology, 2007
- Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-β2 in human retinal pigment epithelial cellsExperimental Eye Research, 2007